Thalidomide 4'-ether-alkylC2-amine hydrochloride - CAS 2341840-99-9

Catalog Number Size Price Stock Quantity
BP-100125 500 mg $1099 In stock
Add to cart

Thalidomide 4'-ether-alkylC2-amine hydrochloride is a synthetic E3 ligand-linker conjugate containing a cereblon ligand based on Thalidomide and a short C2 alkyl linker with terminal amine for covalent binding, as a part of a variety of functionalized PROTAC molecules for binding to a target protein ligand.

* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.

Molecular Formula
Molecular Weight

Thalidomide 4'-ether-alkylC2-amine hydrochloride

    • Specification
      • Purity
        ≥95% by HPLC
        Store at -20°C
        Room temperature in continental US; may vary elsewhere.
        IUPAC Name
        Thalidomide - linker 6
    • Properties
      • InChI Key
        Canonical SMILES
    • Reference Reading
      • 1. Mantle Cell Lymphoma
        John F Seymour, Michael L Wang, Chan Yoon Cheah J Clin Oncol . 2016 Apr 10;34(11):1256-69. doi: 10.1200/JCO.2015.63.5904.
        Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma previously considered to have a poor prognosis. Large gains were made in the first decade of the new century when clinical trials established the importance of high-dose therapy and autologous stem-cell rescue and high-dose cytarabine in younger patients and the benefits of maintenance rituximab and bendamustine in older patients. In particular, greater depth of understanding of the molecular pathophysiology of MCL has resulted in an explosion of specifically targeted new efficacious agents. In particular, agents recently approved by the Food and Drug Administration include the proteasome inhibitor bortezomib, immunomodulator lenalidomide, and Bruton's tyrosine kinase inhibitor ibrutinib. We review recent advances in the understanding of MCL biology and outline our recommended approach to therapy, including choice of chemoimmunotherapy, the role of stem-cell transplantation, and mechanism-based targeted therapies, on the basis of a synthesis of the data from published clinical trials.
        2. Bendamustine in multiple myeloma
        Ernesto Vigna, Massimo Gentile, Francesco Mendicino, Anna Grazia Recchia, Lucio Morabito, Giovanna Giagnuolo, Fortunato Morabito Eur J Haematol . 2015 Nov;95(5):377-88. doi: 10.1111/ejh.12609.
        The advent of high-dose melphalan with autologous stem-cell transplantation (ASCT), the availability of novel agents such as thalidomide, lenalidomide (immunomodulatory drugs or IMiDs) and bortezomib (proteasome inhibitor) and improvements in supportive care have allowed to increase overall survival in multiple myeloma (MM) patients; nevertheless, MM remains an incurable pathology. For this reason, newer agents are required for continued disease control. Bendamustine is an old drug rediscovered in the last decade. In fact, its unique mechanism of action with structural similarities to both alkylating agents and antimetabolities, but which is not cross-resistant to alkylating agents, has reawakened interest in the use of this drug in the treatment of MM. Studies have proven the safety and efficacy of bendamustine administered alone or in combination with new drugs in both upfront and relapse/refractory settings of MM patients, including those with renal impairment. Moreover, bendamustine has been successfully used as conditioning for autologous stem-cell transplantation. Finally, the use of bendamustine does not compromise peripheral blood stem-cell collection. This drug is generally well tolerated, with the majority of adverse events being due to myelosuppression. Non-haematological adverse events are infrequent and usually mild.
        3. Pharmacology of oral chemotherapy agents
        Ann Birner Clin J Oncol Nurs . 2003 Nov-Dec;7(6 Suppl):11-9. doi: 10.1188/03.CJON.S6.11-19.
        The abundance of orally formulated chemotherapy agents reflects the expanding role of oral chemotherapy in the care of patients with cancer. Many oral chemotherapy agents have been used for a number of years, and several have been developed recently. Newer agents include the prodrugs capecitabine and temozolomide, the retinoid bexarotene, the immunomodulatory agent thalidomide, the protein kinase inhibitor imatinib, and the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Each agent has unique pharmacologic properties, dosing, and side-effect profiles. This article reviews these agents from a pharmacology perspective.
Bio Calculators
Stock concentration: *
Desired final volume: *
Desired concentration: *


* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
Tip: Chemical formula is case sensitive. C22H30N4O c22h30n40
Related Products
BOC Sciences Support

Please contact us with any specific requirements and we will get back to you as soon as possible.

  • Verification code

We invite you to contact us at or through our contact form above for more information about our services and products.

  • International:
  • US & Canada (Toll free):
  • Email:
  • Fax:
  • Email:
Inquiry Basket